{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T01:37:28Z","timestamp":1786498648745,"version":"build-2736575974"},"reference-count":143,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,26]],"date-time":"2023-08-26T00:00:00Z","timestamp":1693008000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: CardioOncology"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.jaccao.2023.08.003","type":"journal-article","created":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T05:11:28Z","timestamp":1695791488000},"page":"715-731","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Priorities in Cardio-Oncology Basic and Translational Science"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8947-9315","authenticated-orcid":false,"given":"Fadi N.","family":"Salloum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo G.","family":"Tocchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7167-7287","authenticated-orcid":false,"given":"Pietro","family":"Ameri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Ardehali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aarti","family":"Asnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf A.","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9616-0006","authenticated-orcid":false,"given":"Paul","family":"Burridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9-\u00c1ngel","family":"Cabrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"de Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ra\u00fal","family":"C\u00f3rdoba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambra","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Dent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0289-5210","authenticated-orcid":false,"given":"Daniel","family":"Engelbertsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Fern\u00e1ndez-Velasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8352-8975","authenticated-orcid":false,"given":"Mike","family":"Fradley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5970-629X","authenticated-orcid":false,"given":"Jos\u00e9 J.","family":"Fuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Gal\u00e1n-Arriola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00e9s","family":"Garc\u00eda-Lunar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Ghigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Gonz\u00e1lez-Neira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9073-6024","authenticated-orcid":false,"given":"Emilio","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borja","family":"Ib\u00e1\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard N.","family":"Kitsis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suma","family":"Konety","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander R.","family":"Lyon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2392-1764","authenticated-orcid":false,"given":"Pilar","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adolfo G.","family":"Mauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel M.","family":"Mazo Vega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter C.","family":"Meijers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas G.","family":"Neilan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tienush","family":"Rassaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Ricke-Hoch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Sepulveda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paaladinesh","family":"Thavendiranathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"van der Meer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin","family":"Fuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie","family":"Ky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"L\u00f3pez-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaccao.2023.08.003_bib1","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jaccao.2023.08.003_bib2","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/CRD.0000000000000239","article-title":"Cardiotoxicity of cancer therapies","volume":"27","author":"Mondal","year":"2019","journal-title":"Cardiol Rev"},{"key":"10.1016\/j.jaccao.2023.08.003_bib3","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1016\/S1470-2045(23)00012-8","article-title":"Systematic review and updated recommendations for cardiomyopathy surveillance for survivors of childhood, adolescent, and young adult cancer from the International Late Effects of Childhood Cancer Guideline Harmonization Group","volume":"24","author":"Ehrhardt","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaccao.2023.08.003_bib4","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jaccao.2023.08.003_bib5","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/bs.acr.2022.03.006","article-title":"Cardiac complications of cancer therapies","volume":"155","author":"Mauro","year":"2022","journal-title":"Adv Cancer Res"},{"key":"10.1016\/j.jaccao.2023.08.003_bib6","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.tox.2016.10.001","article-title":"An integrative view of cisplatin-induced renal and cardiac toxicities: molecular mechanisms, current treatment challenges and potential protective measures","volume":"371","author":"Dugbartey","year":"2016","journal-title":"Toxicology"},{"key":"10.1016\/j.jaccao.2023.08.003_bib7","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3389\/fcvm.2020.00026","article-title":"Cardiotoxicity of anthracyclines","volume":"7","author":"Cardinale","year":"2020","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jaccao.2023.08.003_bib8","doi-asserted-by":"crossref","first-page":"aad0116","DOI":"10.1126\/science.aad0116","article-title":"Imbalanced\u00a0OPA1 processing and mitochondrial fragmentation cause heart failure in mice","volume":"350","author":"Wai","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.jaccao.2023.08.003_bib9","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10565-006-0140-y","article-title":"Adriamycin-induced oxidative mitochondrial cardiotoxicity","volume":"23","author":"Berthiaume","year":"2007","journal-title":"Cell Biol Toxicol"},{"key":"10.1016\/j.jaccao.2023.08.003_bib10","first-page":"10","article-title":"The role of iron in doxorubicin-induced cardiomyopathy","volume":"25","author":"Myers","year":"1998","journal-title":"Semin Oncol"},{"key":"10.1016\/j.jaccao.2023.08.003_bib11","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.jacc.2018.11.046","article-title":"Serial magnetic resonance imaging to identify early stages of anthracycline-induced cardiotoxicity","volume":"73","author":"Gal\u00e1n-Arriola","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2023.08.003_bib12","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1093\/cvr\/cvaa181","article-title":"Remote ischaemic preconditioning ameliorates anthracycline-induced cardiotoxicity and preserves mitochondrial integrity","volume":"117","author":"Gal\u00e1n-Arriola","year":"2021","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jaccao.2023.08.003_bib13","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1161\/CIRCULATIONAHA.117.030352","article-title":"Phosphoinositide 3-kinase gamma inhibition protects from anthracycline cardiotoxicity and reduces tumor growth","volume":"138","author":"Li","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2023.08.003_bib14","doi-asserted-by":"crossref","DOI":"10.1126\/science.abk0410","article-title":"PI(3,4)P2-mediated cytokinetic abscission prevents early senescence and cataract formation","volume":"374","author":"Gulluni","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.jaccao.2023.08.003_bib15","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/j.jacc.2021.07.042","article-title":"Coronary microvascular dysfunction across the spectrum of cardiovascular diseases: JACC State-of-the-Art Review","volume":"78","author":"Del Buono","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2023.08.003_bib16","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/cvr\/cvab053","article-title":"Coronary microcirculation damage in anthracycline cardiotoxicity","volume":"118","author":"Gal\u00e1n-Arriola","year":"2022","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jaccao.2023.08.003_bib17","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1161\/CIRCULATIONAHA.109.902221","article-title":"Juvenile exposure to anthracyclines impairs cardiac progenitor cell function and vascularization resulting in greater susceptibility to stress-induced myocardial injury in adult mice","volume":"121","author":"Huang","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2023.08.003_bib18","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1007\/s12350-018-1458-6","article-title":"Rubidium-82 positron emission tomography for detection of acute doxorubicin-induced cardiac effects in lymphoma patients","volume":"27","author":"Laursen","year":"2020","journal-title":"J\u00a0Nucl Cardiol"},{"key":"10.1016\/j.jaccao.2023.08.003_bib19","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.ijrobp.2021.08.039","article-title":"Cardiac magnetic resonance imaging and blood biomarkers for evaluation of radiation-induced cardiotoxicity in patients with breast cancer: results of a phase 2 clinical trial","volume":"112","author":"Speers","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jaccao.2023.08.003_bib20","first-page":"861","article-title":"Role of endothelium in doxorubicin-induced cardiomyopathy","volume":"3","author":"Luu","year":"2018","journal-title":"J\u00a0Am Coll Cardiol Basic Trans Science"},{"key":"10.1016\/j.jaccao.2023.08.003_bib21","first-page":"4070","article-title":"Subclinical doxorubicin-induced cardiotoxicity update: role of neutrophils and endothelium","volume":"11","author":"Todorova","year":"2021","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.jaccao.2023.08.003_bib22","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.93098","article-title":"Insulin supplementation attenuates cancer-induced cardiomyopathy and slows tumor disease progression","volume":"2","author":"Thackeray","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.jaccao.2023.08.003_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2019.07.014","article-title":"Modulation of cardiac AKT and STAT3 signalling in preclinical cancer models and their impact on the heart","volume":"1867","author":"Pietzsch","year":"2020","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"10.1016\/j.jaccao.2023.08.003_bib24","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12943-020-01258-7","article-title":"Targeting stat3 in cancer immunotherapy","volume":"19","author":"Zou","year":"2020","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jaccao.2023.08.003_bib25","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1158\/0008-5472.CAN-18-2738","article-title":"AKT as a therapeutic target for cancer","volume":"79","author":"Song","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.jaccao.2023.08.003_bib26","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41568-019-0216-7","article-title":"The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism","volume":"20","author":"Hoxhaj","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jaccao.2023.08.003_bib27","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/gt.2011.15","article-title":"Lentiviral vectors for induction of self-differentiation and conditional ablation of dendritic cells","volume":"18","author":"Pincha","year":"2011","journal-title":"Gene Ther"},{"key":"10.1016\/j.jaccao.2023.08.003_bib28","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00395-021-00902-7","article-title":"Anthracycline-free tumor elimination in mice leads to functional and molecular cardiac recovery from cancer-induced alterations in contrast to long-lasting doxorubicin treatment effects","volume":"116","author":"Pietzsch","year":"2021","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.jaccao.2023.08.003_bib29","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s00204-019-02626-z","article-title":"Doxorubicin persistently rewires cardiac circadian homeostasis in mice","volume":"94","author":"Ferreira","year":"2020","journal-title":"Arch Toxicol"},{"key":"10.1016\/j.jaccao.2023.08.003_bib30","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.jcmg.2021.02.031","article-title":"Clinical validation of a 3-dimensional ultrafast cardiac magnetic resonance protocol including single breath-hold 3-dimensional sequences","volume":"14","author":"G\u00f3mez-Talavera","year":"2021","journal-title":"J\u00a0Am Coll Cardiol Img"},{"key":"10.1016\/j.jaccao.2023.08.003_bib31","first-page":"221","article-title":"Remote ischemic pre-conditioning attenuates adverse cardiac remodeling and mortality following doxorubicin administration in mice","volume":"1","author":"Gertz","year":"2019","journal-title":"J\u00a0Am Coll Cardiol CardioOnc"},{"key":"10.1016\/j.jaccao.2023.08.003_bib32","first-page":"356","article-title":"Ischemic conditioning for anthracycline-cardiotoxicity: the need to protect the most vulnerable","volume":"5","author":"Ibanez","year":"2023","journal-title":"J\u00a0Am Coll Cardiol CardioOnc"},{"key":"10.1016\/j.jaccao.2023.08.003_bib33","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11912-020-0897-9","article-title":"Immune-related adverse events (irAEs): diagnosis, management, and clinical pearls","volume":"22","author":"Darnell","year":"2020","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.jaccao.2023.08.003_bib34","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/s41569-022-00698-6","article-title":"Cardio-onco-metabolism: metabolic remodelling in cardiovascular disease and cancer","volume":"19","author":"Karlstaedt","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jaccao.2023.08.003_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0221940","article-title":"Doxorubicin induces trans-differentiation and MMP1 expression in cardiac fibroblasts via cell death-independent pathways","volume":"14","author":"Narikawa","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.jaccao.2023.08.003_bib36","doi-asserted-by":"crossref","first-page":"H1091","DOI":"10.1152\/ajpheart.00312.2022","article-title":"Smad3 promotes adverse cardiovascular remodeling and dysfunction in doxorubicin-treated hearts","volume":"323","author":"Cobb","year":"2022","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jaccao.2023.08.003_bib37","article-title":"Testosterone antagonizes doxorubicin-induced senescence of cardiomyocytes","volume":"5","author":"Altieri","year":"2016","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jaccao.2023.08.003_bib38","doi-asserted-by":"crossref","first-page":"5237","DOI":"10.7150\/thno.70884","article-title":"Stress-induced premature senescence is associated with a prolonged QT interval and recapitulates features of cardiac aging","volume":"12","author":"Lazzarini","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.jaccao.2023.08.003_bib39","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/sj.clpt.6100067","article-title":"Plasma and tissue pharmacokinetics of epirubicin and paclitaxel in patients receiving neoadjuvant chemotherapy for locally advanced primary breast cancer","volume":"81","author":"Hunz","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jaccao.2023.08.003_bib40","first-page":"3417","article-title":"Plasma pharmacokinetics of adriamycin and adriamycinol: implications for the design of in\u00a0vitro experiments and treatment protocols","volume":"43","author":"Greene","year":"1983","journal-title":"Cancer Res"},{"key":"10.1016\/j.jaccao.2023.08.003_bib41","doi-asserted-by":"crossref","first-page":"C380","DOI":"10.1152\/ajpcell.00073.2019","article-title":"Accelerated cardiomyocyte senescence contributes to late-onset doxorubicin-induced cardiotoxicity","volume":"318","author":"Mitry","year":"2020","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.jaccao.2023.08.003_bib42","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1158\/2159-8290.CD-16-0241","article-title":"Cellular senescence promotes adverse effects of chemotherapy and cancer relapse","volume":"7","author":"Demaria","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jaccao.2023.08.003_bib43","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.cardfail.2016.04.008","article-title":"Models of heart failure based on the cardiotoxicity of anticancer drugs","volume":"22","author":"Mercurio","year":"2016","journal-title":"J\u00a0Card Fail"},{"issue":"3","key":"10.1016\/j.jaccao.2023.08.003_bib44","first-page":"298","article-title":"Evaluation of senescence and its prevention in doxorubicin-induced cardiotoxicity using dynamic engineered heart tissues","volume":"5","author":"Linders","year":"2023","journal-title":"J\u00a0Am Coll Cardiol CardioOnc"},{"key":"10.1016\/j.jaccao.2023.08.003_bib45","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1126\/scitranslmed.abd1817","article-title":"Dynamic loading of human engineered heart tissue enhances contractile function and drives a desmosome-linked disease phenotype","volume":"13","author":"Bliley","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaccao.2023.08.003_bib46","doi-asserted-by":"crossref","DOI":"10.1172\/JCI140615","article-title":"Gain-of-function mutation in ubiquitin ligase KLHL24 causes desmin degradation and dilatation in hiPSC-derived engineered heart tissues","volume":"131","author":"Vermeer","year":"2021","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jaccao.2023.08.003_bib47","doi-asserted-by":"crossref","first-page":"9634","DOI":"10.18632\/oncotarget.7457","article-title":"GDF15 contributes to radiation-induced senescence through the ROS-mediated p16 pathway in human endothelial cells","volume":"7","author":"Park","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jaccao.2023.08.003_bib48","article-title":"Changes in cardiovascular biomarkers with breast cancer therapy and associations with cardiac dysfunction","volume":"9","author":"Demissei","year":"2020","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jaccao.2023.08.003_bib49","first-page":"539","article-title":"Genetics of anthracycline cardiomyopathy in cancer survivors: JACC: CardioOncology State-of-the-Art Review","volume":"2","author":"Bhatia","year":"2020","journal-title":"J\u00a0Am Coll Cardiol CardioOnc"},{"key":"10.1016\/j.jaccao.2023.08.003_bib50","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/bjh.12516","article-title":"Genetic susceptibility to anthracycline-related congestive heart failure in survivors of haematopoietic cell transplantation","volume":"163","author":"Armenian","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaccao.2023.08.003_bib51","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/ng.3374","article-title":"A\u00a0coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer","volume":"47","author":"Aminkeng","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.jaccao.2023.08.003_bib52","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1200\/JCO.2010.34.3467","article-title":"Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children","volume":"30","author":"Visscher","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaccao.2023.08.003_bib53","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1002\/cncr.28256","article-title":"Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia","volume":"119","author":"Lipshultz","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.jaccao.2023.08.003_bib54","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1161\/CIRCULATIONAHA.118.037934","article-title":"Genetic variants associated with cancer therapy-induced cardiomyopathy","volume":"140","author":"Garcia-Pavia","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2023.08.003_bib55","first-page":"76","article-title":"Contribution of polygenic risk to hypertension among long-term survivors of childhood cancer","volume":"3","author":"Sapkota","year":"2021","journal-title":"J\u00a0Am Coll Cardiol CardioOnc"},{"key":"10.1016\/j.jaccao.2023.08.003_bib56","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1200\/JCO.22.01527","article-title":"Genome-wide association study identifies ROBO2 as a novel susceptibility gene for anthracycline-related cardiomyopathy in childhood cancer survivors","volume":"41","author":"Wang","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaccao.2023.08.003_bib57","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/ni.1817","article-title":"Mechanisms maintaining peripheral tolerance","volume":"11","author":"Mueller","year":"2010","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jaccao.2023.08.003_bib58","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.589641","article-title":"Revisiting T cell tolerance as a checkpoint target for cancer immunotherapy","volume":"11","author":"N\u00fcssing","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaccao.2023.08.003_bib59","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jaccao.2023.08.003_bib60","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.851032","article-title":"A\u00a0Systematic review of the mechanisms involved in immune checkpoint inhibitors cardiotoxicity and challenges to improve clinical safety","volume":"10","author":"Rubio-Infante","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.jaccao.2023.08.003_bib61","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-96467-5","article-title":"Myocarditis occurrence with cancer immunotherapy across indications in clinical trial and post-marketing data","volume":"11","author":"Makunts","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.jaccao.2023.08.003_bib62","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jaccao.2023.08.003_bib63","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/eurheartj\/ehaa051","article-title":"Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis","volume":"41","author":"Zhang","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jaccao.2023.08.003_bib64","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","article-title":"Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement","volume":"43","author":"Herrmann","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jaccao.2023.08.003_bib65","first-page":"624","article-title":"What is the evidence of the diagnostic criteria and screening of immune checkpoint inhibitor-induced myocarditis?","volume":"4","author":"Thuny","year":"2022","journal-title":"J\u00a0Am Coll Cardiol CardioOnc"},{"key":"10.1016\/j.jaccao.2023.08.003_bib66","first-page":"157","article-title":"Management of immune checkpoint inhibitor-induced myocarditis: the French Working Group\u2019s plea for a pragmatic approach","volume":"3","author":"Thuny","year":"2021","journal-title":"J\u00a0Am Coll Cardiol CardioOnc"},{"key":"10.1016\/j.jaccao.2023.08.003_bib67","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1158\/2159-8290.CD-20-0856","article-title":"A\u00a0genetic mouse model recapitulates immune checkpoint inhibitor-associated myocarditis and supports a mechanism-based therapeutic intervention","volume":"11","author":"Wei","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jaccao.2023.08.003_bib68","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/s41586-022-05432-3","article-title":"T\u00a0cells specific for \u03b1-myosin drive immunotherapy-related myocarditis","volume":"611","author":"Axelrod","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.jaccao.2023.08.003_bib69","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1161\/CIRCULATIONAHA.121.056730","article-title":"Identification of pathogenic immune cell subsets associated with checkpoint inhibitor-induced myocarditis","volume":"146","author":"Zhu","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2023.08.003_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111611","article-title":"Cardiac myosin-specific autoimmune T cells contribute to immune-checkpoint-inhibitor-associated myocarditis","volume":"41","author":"Won","year":"2022","journal-title":"Cell Rep"},{"key":"10.1016\/j.jaccao.2023.08.003_bib71","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2023.08.003_bib72","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1361097","article-title":"Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab","volume":"6","author":"Reuben","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jaccao.2023.08.003_bib73","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1172\/JCI44583","article-title":"Impaired thymic tolerance to \u03b1-myosin directs autoimmunity to the heart in mice and humans","volume":"121","author":"Lv","year":"2011","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jaccao.2023.08.003_bib74","doi-asserted-by":"crossref","first-page":"4494","DOI":"10.3390\/cancers14184494","article-title":"Pathophysiology of immune checkpoint inhibitor-induced myocarditis","volume":"14","author":"Jim\u00e9nez-Alejandre","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jaccao.2023.08.003_bib75","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41569-020-0352-5","article-title":"T\u00a0cell subsets and functions in atherosclerosis","volume":"17","author":"Saigusa","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jaccao.2023.08.003_bib76","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1161\/CIRCRESAHA.121.320090","article-title":"Human coronary plaque T cells are clonal and cross-react to virus and self","volume":"130","author":"Chowdhury","year":"2022","journal-title":"Circ Res"},{"key":"10.1016\/j.jaccao.2023.08.003_bib77","first-page":"598","article-title":"Atherosclerosis with immune checkpoint inhibitor therapy: evidence, diagnosis, and management: JACC: CardioOncology State-of-the-Art Review","volume":"4","author":"Suero-Abreu","year":"2022","journal-title":"J\u00a0Am Coll Cardiol CardioOnc"},{"key":"10.1016\/j.jaccao.2023.08.003_bib78","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1161\/CIRCULATIONAHA.120.049981","article-title":"Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque","volume":"142","author":"Drobni","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2023.08.003_bib79","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/j.jacc.2019.07.056","article-title":"Cardiovascular toxicities associated with ibrutinib","volume":"74","author":"Salem","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2023.08.003_bib80","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1161\/ATVBAHA.111.224709","article-title":"Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation","volume":"31","author":"Bu","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jaccao.2023.08.003_bib81","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1161\/ATVBAHA.115.306848","article-title":"Overexpression of cytotoxic T-lymphocyte-associated antigen-4 prevents atherosclerosis in mice","volume":"36","author":"Matsumoto","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jaccao.2023.08.003_bib82","first-page":"635","article-title":"LAG3 regulates T cell activation and plaque infiltration in atherosclerotic mice","volume":"4","author":"Mulholland","year":"2022","journal-title":"J\u00a0Am Coll Cardiol CardioOnc"},{"key":"10.1016\/j.jaccao.2023.08.003_bib83","first-page":"599","article-title":"Immune checkpoint inhibitor therapy aggravates T cell-driven plaque inflammation in atherosclerosis","volume":"2","author":"Poels","year":"2020","journal-title":"J\u00a0Am Coll Cardiol CardioOnc"},{"key":"10.1016\/j.jaccao.2023.08.003_bib84","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.740531","article-title":"Stimulation of the PD-1 pathway decreases atherosclerotic lesion development in ldlr deficient mice","volume":"8","author":"Grievink","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jaccao.2023.08.003_bib85","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","article-title":"Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade","volume":"20","author":"Miller","year":"2019","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jaccao.2023.08.003_bib86","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41586-021-04248-x","article-title":"An autoimmune stem-like CD8\u00a0T cell population drives type 1 diabetes","volume":"602","author":"Gearty","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.jaccao.2023.08.003_bib87","doi-asserted-by":"crossref","first-page":"E41","DOI":"10.1161\/CIR.0000000000000986","article-title":"Recognition, prevention, and management of arrhythmias and autonomic disorders in cardio-oncology: a scientific statement from the American Heart Association","volume":"144","author":"Fradley","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2023.08.003_bib88","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/eurheartj\/ehab745","article-title":"Incidence, risk factors, and mortality of atrial fibrillation in breast cancer: a SEER-Medicare analysis","volume":"43","author":"Guha","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jaccao.2023.08.003_bib89","first-page":"619","article-title":"Common pathophysiology in cancer, atrial fibrillation, atherosclerosis, and thrombosis: JACC: CardioOncology State-of-the-Art Review","volume":"3","author":"Leiva","year":"2021","journal-title":"J\u00a0Am Coll Cardiol CardioOnc"},{"key":"10.1016\/j.jaccao.2023.08.003_bib90","first-page":"221","article-title":"Risk of atrial fibrillation according to cancer type: a nationwide population-based study","volume":"3","author":"Yun","year":"2021","journal-title":"J\u00a0Am Coll Cardiol CardioOnc"},{"key":"10.1016\/j.jaccao.2023.08.003_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2022.100026","article-title":"Atrial fibrillation and cancer: prevalence and relative risk from a nationwide study","volume":"7","author":"Ay","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jaccao.2023.08.003_bib92","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1093\/ehjcvp\/pvaa037","article-title":"Identification of anticancer drugs associated with atrial fibrillation: analysis of the WHO pharmacovigilance database","volume":"7","author":"Alexandre","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jaccao.2023.08.003_bib93","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.amjcard.2019.05.029","article-title":"Rates and risk of atrial arrhythmias in patients treated with ibrutinib compared with cytotoxic chemotherapy","volume":"124","author":"Fradley","year":"2019","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jaccao.2023.08.003_bib94","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1161\/CIRCULATIONAHA.120.049210","article-title":"Ibrutinib-mediated atrial fibrillation attributable to inhibition of C-terminal Src kinase","volume":"142","author":"Xiao","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2023.08.003_bib95","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1161\/CIRCULATIONAHA.117.030571","article-title":"Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity","volume":"136","author":"Escudier","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2023.08.003_bib96","article-title":"Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States","volume":"6","author":"Jain","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.jaccao.2023.08.003_bib97","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/jcmm.12467","article-title":"PD-1\/PD-L1 expression on CD4+ T cells and myeloid DCs correlates with the immune pathogenesis of atrial fibrillation","volume":"19","author":"Liu","year":"2015","journal-title":"J\u00a0Cell Mol Med"},{"key":"10.1016\/j.jaccao.2023.08.003_bib98","doi-asserted-by":"crossref","first-page":"3915","DOI":"10.1093\/eurheartj\/ehab362","article-title":"Anticancer drug-induced life-threatening ventricular arrhythmias: a World Health Organization pharmacovigilance study","volume":"42","author":"Salem","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jaccao.2023.08.003_bib99","article-title":"Incidence, diagnosis, and management of QT prolongation induced by cancer therapies: a systematic review","volume":"6","author":"Porta-S\u00e1nchez","year":"2017","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jaccao.2023.08.003_bib100","first-page":"50","article-title":"Increased incidence of ventricular arrhythmias in patients with advanced cancer and implantable cardioverter-defibrillators","volume":"3","author":"Enriquez","year":"2017","journal-title":"J\u00a0Am Coll Cardiol EP"},{"key":"10.1016\/j.jaccao.2023.08.003_bib101","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.jacc.2018.06.002","article-title":"Ventricular arrhythmias following ibrutinib initiation for lymphoid malignancies","volume":"72","author":"Guha","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2023.08.003_bib102","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1182\/blood-2016-10-742437","article-title":"Ventricular arrhythmias and sudden death in patients taking ibrutinib","volume":"129","author":"Lampson","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2023.08.003_bib103","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1182\/blood.2022016953","article-title":"Ventricular arrhythmias and sudden death events following acalabrutinib initiation","volume":"140","author":"Bhat","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2023.08.003_bib104","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1002\/ejhf.2029","article-title":"Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart\u00a0Failure Association (HFA) of the European Society of Cardiology (ESC)","volume":"22","author":"de Boer","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jaccao.2023.08.003_bib105","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1093\/cvr\/cvz035","article-title":"Common risk factors for heart failure and cancer","volume":"115","author":"Meijers","year":"2019","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jaccao.2023.08.003_bib106","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/ejhf.1539","article-title":"Cancer and heart disease: associations and relations","volume":"21","author":"de Boer","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jaccao.2023.08.003_bib107","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yjmcc.2021.09.008","article-title":"Reverse cardio-oncology: Exploring the effects of cardiovascular disease on cancer pathogenesis","volume":"163","author":"Koelwyn","year":"2022","journal-title":"J\u00a0Mol Cell Cardiol"},{"key":"10.1016\/j.jaccao.2023.08.003_bib108","first-page":"98","article-title":"Cancer incidence and mortality according to pre-existing heart failure in a community-based cohort","volume":"4","author":"Bertero","year":"2022","journal-title":"J\u00a0Am Coll Cardiol CardioOnc"},{"key":"10.1016\/j.jaccao.2023.08.003_bib109","first-page":"69","article-title":"Association of cardiometabolic disease with cancer in the community","volume":"4","author":"Liu","year":"2022","journal-title":"J\u00a0Am Coll Cardiol CardioOnc"},{"issue":"Suppl 1","key":"10.1016\/j.jaccao.2023.08.003_bib110","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1016\/j.thromres.2021.12.009","article-title":"Clonal hematopoiesis and cardiovascular disease in cancer patients and survivors","volume":"213","author":"Fuster","year":"2022","journal-title":"Thromb Res"},{"key":"10.1016\/j.jaccao.2023.08.003_bib111","doi-asserted-by":"crossref","first-page":"aan4673","DOI":"10.1126\/science.aan4673","article-title":"Clonal hematopoiesis in\u00a0human aging and disease","volume":"366","author":"Jaiswal","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.jaccao.2023.08.003_bib112","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s44161-021-00015-3","article-title":"Clonal hematopoiesis in cardiovascular disease and therapeutic implications","volume":"1","author":"Tall","year":"2022","journal-title":"Nat Cardiovasc Res"},{"key":"10.1016\/j.jaccao.2023.08.003_bib113","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.stem.2017.07.010","article-title":"Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes","volume":"21","author":"Coombs","year":"2017","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.jaccao.2023.08.003_bib114","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00395-022-00969-w","article-title":"Clonal hematopoiesis and cardiovascular disease: deciphering interconnections","volume":"117","author":"Stein","year":"2022","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.jaccao.2023.08.003_bib115","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s44161-022-00206-6","article-title":"TP53- mediated clonal hematopoiesis confers increased risk for incident atherosclerotic disease","volume":"2","author":"Zekavat","year":"2023","journal-title":"Nat Cardiovasc Res"},{"key":"10.1016\/j.jaccao.2023.08.003_bib116","doi-asserted-by":"crossref","first-page":"e146076","DOI":"10.1172\/jci.insight.146076","article-title":"TP53-mediated therapy-related clonal hematopoiesis contributes to doxorubicin-induced cardiomyopathy by augmenting a neutrophil-mediated cytotoxic response","volume":"6","author":"Sano","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.jaccao.2023.08.003_bib117","first-page":"38","article-title":"Cardiovascular disease among patients with AML and CHIP-related mutations","volume":"4","author":"Calvillo-Arg\u00fcelles","year":"2022","journal-title":"J\u00a0Am Coll Cardiol CardioOnc"},{"key":"10.1016\/j.jaccao.2023.08.003_bib118","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1158\/2159-8290.CD-22-0956","article-title":"Dynamics of age- versus therapy-related clonal hematopoiesis in long-term survivors of pediatric cancer","volume":"13","author":"Hagiwara","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jaccao.2023.08.003_bib119","first-page":"1623","article-title":"What to tell your patient with clonal hematopoiesis and why: insights from 2 specialized clinics","volume":"136","author":"Steensma","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2023.08.003_bib120","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/ejhf.472","article-title":"Incidence of cancer in patients with chronic heart failure: a long-term follow-up study","volume":"18","author":"Banke","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jaccao.2023.08.003_bib121","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1161\/CIRCULATIONAHA.117.030816","article-title":"Heart failure stimulates tumor growth by circulating factors","volume":"138","author":"Meijers","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2023.08.003_bib122","article-title":"Stress echocardiography positivity predicts cancer death","volume":"6","author":"Carpeggiani","year":"2017","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jaccao.2023.08.003_bib123","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1161\/CIRCULATIONAHA.120.053315","article-title":"From studying heart disease and cancer simultaneously to reverse cardio-oncology","volume":"144","author":"De Wit","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2023.08.003_bib124","doi-asserted-by":"crossref","first-page":"E21","DOI":"10.1161\/RES.0000000000000473","article-title":"Preclinical models of cancer therapy-associated cardiovascular toxicity: a scientific statement from the American Heart Association","volume":"129","author":"Asnani","year":"2021","journal-title":"Circ Res"},{"key":"10.1016\/j.jaccao.2023.08.003_bib125","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1093\/cvr\/cvaa222","article-title":"Cardiac dysfunction in cancer patients: Beyond direct cardiomyocyte damage of anticancer drugs: Novel cardio-oncology insights from the joint 2019 meeting of the ESC working groups of myocardial function and cellular biology of the heart","volume":"116","author":"Tocchetti","year":"2020","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jaccao.2023.08.003_bib126","first-page":"130","article-title":"How to apply translational models to probe mechanisms of cardiotoxicity","volume":"4","author":"Livingston","year":"2022","journal-title":"J\u00a0Am Coll Cardiol CardioOnc"},{"key":"10.1016\/j.jaccao.2023.08.003_bib127","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nm.4087","article-title":"Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity","volume":"22","author":"Burridge","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.jaccao.2023.08.003_bib128","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1161\/CIRCULATIONAHA.121.055801","article-title":"Identification of drug transporter genomic variants and inhibitors that protect against doxorubicin-induced cardiotoxicity","volume":"145","author":"Magdy","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2023.08.003_bib129","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1161\/CIRCRESAHA.122.320305","article-title":"Cellular and engineered organoids for cardiovascular models","volume":"130","author":"Thomas","year":"2022","journal-title":"Circ Res"},{"key":"10.1016\/j.jaccao.2023.08.003_bib130","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/s41551-020-0539-4","article-title":"Human cardiac organoids for the modelling of myocardial infarction and drug cardiotoxicity","volume":"4","author":"Richards","year":"2020","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.jaccao.2023.08.003_bib131","doi-asserted-by":"crossref","first-page":"955","DOI":"10.3389\/fbioe.2020.00955","article-title":"Cells, materials, and fabrication processes for cardiac tissue engineering","volume":"8","author":"Montero","year":"2020","journal-title":"Front Bioeng Biotechnol"},{"key":"10.1016\/j.jaccao.2023.08.003_bib132","article-title":"3D printing of personalized thick and perfusable cardiac patches and hearts","volume":"6","author":"Noor","year":"2019","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.jaccao.2023.08.003_bib133","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1126\/science.aav9051","article-title":"3D bioprinting of collagen to rebuild components of the human heart","volume":"365","author":"Lee","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.jaccao.2023.08.003_bib134","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1089\/ten.tec.2019.0248","article-title":"Human induced pluripotent stem-cardiac-endothelial-tumor-on-a-chip to assess anticancer efficacy and cardiotoxicity","volume":"26","author":"Weng","year":"2020","journal-title":"Tissue Eng Part C Methods"},{"key":"10.1016\/j.jaccao.2023.08.003_bib135","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/3820591","article-title":"Preparation and evaluation of animal models of cardiotoxicity in antineoplastic therapy","volume":"2022","author":"Meng","year":"2022","journal-title":"Oxid Med Cell Longev"},{"key":"10.1016\/j.jaccao.2023.08.003_bib136","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s10549-021-06427-w","article-title":"Trastuzumab does not bind rat or mouse ErbB2\/neu: implications for selection of non-clinical safety models for trastuzumab-based therapeutics","volume":"191","author":"Phillips","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jaccao.2023.08.003_bib137","first-page":"1550","article-title":"Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2\/neu gene product","volume":"50","author":"Fendly","year":"1990","journal-title":"Cancer Res"},{"key":"10.1016\/j.jaccao.2023.08.003_bib138","first-page":"149","article-title":"Cardiometabolic comorbidities in cancer survivors: JACC: CardioOncology State-of-the-Art Review","volume":"4","author":"Zullig","year":"2022","journal-title":"J\u00a0Am Coll Cardiol CardioOnc"},{"key":"10.1016\/j.jaccao.2023.08.003_bib139","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1080\/07347332.2012.761322","article-title":"Stress coping and changes in health behavior among cancer survivors: a report from the American Cancer Society\u2019s Study of Cancer Survivors-II (SCS-II)","volume":"31","author":"Parelkar","year":"2013","journal-title":"J\u00a0Psychosoc Oncol"},{"key":"10.1016\/j.jaccao.2023.08.003_bib140","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11936-019-0724-5","article-title":"Psychosocial stress and cardiovascular disease","volume":"21","author":"Dar","year":"2019","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"10.1016\/j.jaccao.2023.08.003_bib141","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s10741-020-10056-8","article-title":"Psychological stress in heart failure: a potentially actionable disease modifier","volume":"26","author":"Harris","year":"2021","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.jaccao.2023.08.003_bib142","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1007\/s11886-022-01732-2","article-title":"Disparities in cardio-oncology: effects on outcomes and opportunities for improvement","volume":"24","author":"Ahmad","year":"2022","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.jaccao.2023.08.003_bib143","first-page":"201","article-title":"Racial and ethnic disparities in cardio-oncology: a call to action","volume":"3","author":"Fazal","year":"2021","journal-title":"J\u00a0Am Coll Cardiol CardioOnc"}],"container-title":["JACC: CardioOncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087323002491?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087323002491?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T18:55:58Z","timestamp":1762973758000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666087323002491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":143,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S2666087323002491"],"URL":"https:\/\/doi.org\/10.1016\/j.jaccao.2023.08.003","relation":{},"ISSN":["2666-0873"],"issn-type":[{"value":"2666-0873","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Priorities in Cardio-Oncology Basic and Translational Science","name":"articletitle","label":"Article Title"},{"value":"JACC: CardioOncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaccao.2023.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}